Immunogen Inc $10.89

down -0.49


24/7/2014 04:00 PM  |  NASDAQ : IMGN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get IMGN Trend Analysis - it has underperformed the S&P 500 by 60%

Partner Headlines

  1. Wednesday's Biggest Movers

    Benzinga
  2. Shares Of ImmunoGen Down On Morgan Stanley's Bearish Initiation

    Benzinga
  3. Benzinga's Top Initiations

    Benzinga
  4. UPDATE: Canaccord Genuity Initiates Coverage on ImmunoGen Ahead of Phase ...

    Benzinga
  5. ImmunoGen Says Initial Research Shows New Dosing Approach for IMGN853 Achieves ...

    Benzinga
  6. IDEXX Laboratories Elects Daniel Junius to Board of Directors

    Benzinga
  7. US Stock Futures Down Ahead Of Wal-Mart Earnings, Economic Data

    Benzinga
  8. CytomX Therapeutics, ImmunoGen Announce Strategic Collaboration

    Benzinga
  9. ImmunoGen Announces Activity Reported with SAR3419 Plus Rituxan In Difficult-to-Treat ...

    Benzinga
  10. US Stock Futures Edge Lower Ahead Of FOMC Minutes, Economic Data

    Benzinga
  11. ImmunoGen Announces Approval of Roche's Kadcyla in EU

    Benzinga
  12. UPDATE: Morgan Stanley Downgrades ImmunoGen Following Phase 2 Failure of ...

    Benzinga
  13. Benzinga's Top #PreMarket Losers

    Benzinga
  14. ImmunoGen Announces License Agreement with Novartis

    Benzinga
  15. Mid-Afternoon Market Update: Marvell Rises on KKR Stake While Orbitz Gives ...

    Benzinga
  16. Mid-Day Market Update: BroadSoft Drops On Q3 Results; Endo Health Shares ...

    Benzinga
  17. Mid-Morning Market Update: Markets Open Lower; CVS Caremark Lifts Outlook

    Benzinga
  18. Benzinga's Top #PreMarket Losers

    Benzinga
  19. US Stock Futures Signal Lower Start On Wall Street

    Benzinga
  20. ImmunoGen Presents SAR566658 Clinical Findings at AACR-NCI-EORTC Conference ...

    Benzinga
  21. US Stock Futures Up; J.P. Morgan Earnings In Focus

    Benzinga
  22. ImmunoGen Announces New License Agreement with Novartis

    Benzinga
  23. ImmunoGen Announces Positive Results from Kadcyla Phase III Trial, TH3RESA ...

    Benzinga
  24. The 'L' In CANSLIM Stands For Leaders, Not Laggards

    IBD
  25. UPDATE: Oppenheimer Downgrades ImmunoGen to Perform on Valuation

    Benzinga
  26. Earnings Scheduled For January 25, 2013

    Benzinga
  27. From Earlier: Amgen Takes Third License for Rights to Use ImmunoGen's TAP ...

    Benzinga
  28. ImmunoGen Clinical Results of IMGN901

    Benzinga
  29. A Peek Into the Market Before the Trading Begins

    Benzinga
  30. ImmunoGen Announces Dr. Charles Morris as New Chief Development Officer

    Benzinga
  31. ImmunoGen Inc. Reports Operating Results (10-Q)

    GuruFocus
  32. It's All Bad News For ImmunoGen After 1Q13 Earnings Release

    Benzinga
  33. Health Care Sector Wrap

    FoxBusiness
  34. Benzinga's Top Pre-Market Gainers

    Benzinga
  35. A Peek Into The Market Before The Trading Starts

    Benzinga
  36. ImmunoGen

    IBD
  37. Health Care Sector Wrap

    FoxBusiness
  38. UPDATE: J.P. Morgan Reiterates Neutral Rating, Raises PT on ImmunoGen

    Benzinga
  39. Infosys Ltd ADR, Kroger Among Stocks Down on High Volume Thursday

    FoxBusiness
  40. Benzinga's Top Pre-Market Losers

    Benzinga
  41. ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and ...

    Benzinga
  42. Benzinga's Initiation Summary for June 14, 2012

    Benzinga
  43. UPDATE: Cantor Fitzgerald Initiates Hold, $15 PT on ImmmunoGen; In Need ...

    Benzinga
  44. From Earlier: ImmunoGen Announces Development of Trastuzumab Emtansine ...

    Benzinga
  45. From Earlier: ImmunoGen Announces Results from Trastuzumab Emtansine (T-DM1) ...

    Benzinga
  46. Stocks Set to Close Quarter on High Note with Finish Line (FINL) and Research ...

    MarketIntelligenceCenter
  47. ImmunoGen Inc. Reports Operating Results (10-Q)

    GuruFocus
  48. ImmunoGen Up 7% After Earnings Beat

    Benzinga
  49. ImmunoGen

    IBD
  50. Best Biotech Stocks of 2011

    Benzinga
Trading Center